Aerie Advances to the Next Round in Glaucoma Treatment
Vicente Anido Jr. PhD, Chairman & CEO for Aerie Pharmaceuticals, provides the attendees of the 5th Annual Ophthalmology Innovation Summit with an overview of Aeries rapid changes throughout the past year. Aerie focuses on the treatment of Glaucoma and has two major products, AR-1324 and Latanapross. Having just completed their initial Public Offering, Aerie can now move the two products into clinic and early NDA filing.
Presenter:
Vicente Anido, Jr., PhD
Vicente Anido, Jr., PhD currently serves as CEO and Chairman of the Board of Aerie Pharmaceuticals, Inc., a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.